Skip to content
value.today

Embecta Corp.: peers

Change the peers

Embecta Corp. beside the 7 companies most like it by industry, size and country: every figure with its date and source, its rank in the group and its percentile in its sector and country.

Side by side#

Every figure with its fiscal year or date and its source. Switch to each company's rank in the group, or its percentile in its sector or country. How ranks are worked out.

Embecta Corp., Nautilus Biotechnology, Inc., Viemed Healthcare, Inc., Emergent BioSolutions Inc., Fennec Pharmaceuticals Inc., CapsoVision, Inc., Editas Medicine, Inc., Orthofix Medical Inc. side by side: each figure with its period and source, its rank among these companies and its percentile in the company's sector and country
MeasureEmbecta Corp.base
EMBC · 🇺🇸 US
Percentile in Healthcare
Percentile in USA
Nautilus Biotechnology, Inc.
NAUT · 🇺🇸 US
Percentile in Healthcare
Percentile in USA
Viemed Healthcare, Inc.
VMD · 🇺🇸 US
Percentile in Healthcare
Percentile in USA
Emergent BioSolutions Inc.
EBS · 🇺🇸 US
Percentile in Healthcare
Percentile in USA
Fennec Pharmaceuticals Inc.
FENC · 🇺🇸 US
Percentile in Healthcare
Percentile in USA
CapsoVision, Inc.
CV · 🇺🇸 US
Percentile in Healthcare
Percentile in USA
Editas Medicine, Inc.
EDIT · 🇺🇸 US
Percentile in Healthcare
Percentile in USA
Orthofix Medical Inc.
OFIX · 🇺🇸 US
Percentile in Healthcare
Percentile in USA
Group median
Size
Market cap (Better neither way: ranked highest first)$366 MOct 29, 2026 · Market data6th of 8$368 MOct 28, 2026 · Market data4th of 8$367 MOct 15, 2026 · Market data5th of 8$365 MOct 29, 2026 · Market data7th of 8$374 MOct 31, 2026 · Market data2nd of 8$372 MOct 30, 2026 · Market data3rd of 8$363 MOct 19, 2026 · Market data8th of 8$377 MOct 15, 2026 · Market data1st of 8$368 M8 ranked
Revenue (Better neither way: ranked highest first)$1.1 BFY2025 · SEC1st of 7——$270 MFY2025 · SEC4th of 7$743 MFY2025 · SEC3rd of 7$45 MFY2025 · SEC5th of 7$14 MFY2025 · SEC7th of 7$41 MFY2025 · SEC6th of 7$822 MFY2025 · SEC2nd of 7$270 M7 ranked
Net income (Higher is better)$95 MFY2025 · SEC1st of 8$-59 MFY2025 · SEC6th of 8$15 MFY2025 · SEC3rd of 8$53 MFY2025 · SEC2nd of 8$-10 MFY2025 · SEC4th of 8$-25 MFY2025 · SEC5th of 8$-160 MFY2025 · SEC8th of 8$-92 MFY2025 · SEC7th of 8$-18 M8 ranked
Employees (Better neither way: ranked highest first)1,850September 30, 2025 · Profile2nd of 6130December 31, 2025 · Profile4th of 6——2,416As on 2021 · Profile1st of 635December 31, 2025 · Profile6th of 699December 31, 2025 · Profile5th of 6264As on 2021 · Profile3rd of 6——1976 ranked
Growth
Market cap change, 30 days (Higher is better)————————-2.2%30 days to Oct 31, 2026 · Market dataonly one with it——————-2.2%—
Revenue growth (Higher is better)-3.8%FY2025 · SEC5th of 719th20th————+20.5%FY2025 · SEC2nd of 770th79th-28.8%FY2025 · SEC7th of 78th4th-6.1%FY2025 · SEC6th of 716th16th+15.2%FY2025 · SEC3rd of 759th71st+25.4%FY2025 · SEC1st of 774th83rd+2.9%FY2025 · SEC4th of 732nd38th+2.9%7 ranked
Revenue growth, 3 years a year (Higher is better)-1.5%FY2025 · SEC5th of 623rd28th————+24.9%FY2025 · SEC3rd of 677th89th-12.7%FY2025 · SEC6th of 611th8th+207.2%FY2025 · SEC1st of 699th100th————+27.1%FY2025 · SEC2nd of 679th90th+21.3%FY2025 · SEC4th of 673rd86th+23.1%6 ranked
Earnings per share growth (Higher is better)+20.9%FY2025 · SEC2nd of 262nd64th————+32.1%FY2025 · SEC1st of 271st73rd————————————————————+26.5%2 ranked
Margins and returns
Gross margin (Higher is better)62.6%FY2025 · SEC2nd of 556th77th————57.5%FY2025 · SEC3rd of 549th71st56.1%FY2025 · SEC4th of 546th70th————52.9%FY2025 · SEC5th of 540th66th————68.8%FY2025 · SEC1st of 566th81st57.5%5 ranked
Operating margin (Higher is better)22.4%FY2025 · SEC1st of 791st88th————8.5%FY2025 · SEC3rd of 771st64th13.5%FY2025 · SEC2nd of 780th75th-14.1%FY2025 · SEC5th of 745th24th-188.3%FY2025 · SEC6th of 716th6th-394.9%FY2025 · SEC7th of 78th3rd-9.9%FY2025 · SEC4th of 749th28th-9.9%7 ranked
Net margin (Higher is better)8.8%FY2025 · SEC1st of 778th72nd————5.5%FY2025 · SEC3rd of 771st63rd7.1%FY2025 · SEC2nd of 774th67th-21.8%FY2025 · SEC5th of 742nd21st-186.9%FY2025 · SEC6th of 716th7th-395.0%FY2025 · SEC7th of 78th3rd-11.2%FY2025 · SEC4th of 748th26th-11.2%7 ranked
Free cash flow margin (Higher is better)16.9%FY2025 · SEC2nd of 684th83rd————4.4%FY2025 · SEC3rd of 662nd51st21.1%FY2025 · SEC1st of 689th89th————-169.4%FY2025 · SEC5th of 617th5th-409.3%FY2025 · SEC6th of 68th2nd-0.2%FY2025 · SEC4th of 652nd34th2.1%6 ranked
Return on equity (Higher is better)————-32.3%FY2025 · SEC4th of 652nd23rd10.9%FY2025 · SEC1st of 683rd68th10.5%FY2025 · SEC2nd of 681st66th-65.8%FY2025 · SEC5th of 635th15th————-198.1%FY2025 · SEC6th of 611th5th-19.3%FY2025 · SEC3rd of 661st28th-25.8%6 ranked
Return on invested capital (Higher is better)31.1%FY2025 · SEC1st of 389th89th————12.6%FY2025 · SEC2nd of 356th58th6.4%FY2025 · SEC3rd of 324th25th————————————————12.6%3 ranked
Valuation
P/E ratio (Better neither way: ranked highest first)4.2×price Oct 29, 2026 · Market data3rd of 36th3rd————23.5×price Oct 15, 2026 · Market data2nd of 340th61st————185.1×price Oct 31, 2026 · Market data1st of 395th97th————————————23.5×3 ranked
Price to sales (Better neither way: ranked highest first)0.4×price Oct 29, 2026 · Market data7th of 76th11th————1.2×price Oct 15, 2026 · Market data4th of 720th33rd0.6×price Oct 29, 2026 · Market data5th of 710th18th5.6×price Oct 31, 2026 · Market data3rd of 759th79th26.8×price Oct 30, 2026 · Market data1st of 787th95th7.3×price Oct 19, 2026 · Market data2nd of 766th85th0.5×price Oct 15, 2026 · Market data6th of 77th14th1.2×7 ranked
Price to book (Better neither way: ranked highest first)————2.4×price Oct 28, 2026 · Market data5th of 742nd54th2.6×price Oct 15, 2026 · Market data4th of 744th57th0.7×price Oct 29, 2026 · Market data7th of 713th12th10.5×price Oct 31, 2026 · Market data3rd of 785th90th28.1×price Oct 30, 2026 · Market data1st of 794th97th13.3×price Oct 19, 2026 · Market data2nd of 789th93rd0.8×price Oct 15, 2026 · Market data6th of 716th16th2.6×7 ranked
Free cash flow yield (Higher is better)49.8%price Oct 29, 2026 · Market data1st of 899th99th-14.1%price Oct 28, 2026 · Market data7th of 838th18th3.3%price Oct 15, 2026 · Market data3rd of 880th55th43.0%price Oct 29, 2026 · Market data2nd of 899th98th-0.6%price Oct 31, 2026 · Market data5th of 867th35th-6.2%price Oct 30, 2026 · Market data6th of 851st25th-45.7%price Oct 19, 2026 · Market data8th of 820th8th-0.3%price Oct 15, 2026 · Market data4th of 867th36th-0.5%8 ranked
Financial strength
Debt to equity (Lower is better)————————0.1×FY2025 · SEC1st of 419th13th1.1×FY2025 · SEC3rd of 478th71st————————2.0×FY2025 · SEC4th of 488th86th0.3×FY2025 · SEC2nd of 443rd34th0.7×4 ranked
Net debt to EBITDA (Lower is better)4.2×FY2025 · SEC3rd of 380th74th————-0.0×FY2025 · SEC1st of 326th18th2.0×FY2025 · SEC2nd of 352nd48th————————————————2.0×3 ranked
Interest cover (Higher is better)————————————————-3.0×FY2025 · SEC1st of 263rd35th————-25.9×FY2025 · SEC2nd of 228th13th————-14.5×2 ranked
Piotroski F-score (Higher is better)6 of 9FY2025 · SEC2nd of 4——6 of 9FY2025 · SEC2nd of 48 of 9FY2025 · SEC1st of 4——————5 of 9FY2025 · SEC4th of 46.0 of 94 ranked
Scorecard
Scorecard (Higher is better)16 of 26FY2025 · Scorecard2nd of 83 of 12FY2025 · Scorecard8th of 821 of 26FY2025 · Scorecard1st of 811 of 25FY2025 · Scorecard3rd of 88 of 20FY2025 · Scorecard4th of 83 of 11FY2025 · Scorecard7th of 87 of 22FY2025 · Scorecard6th of 88 of 21FY2025 · Scorecard5th of 839% passed8 ranked
Valuation checks (Higher is better)4 of 6FY2025 · Scorecard1st of 81 of 4FY2025 · Scorecard5th of 84 of 6FY2025 · Scorecard1st of 83 of 5FY2025 · Scorecard3rd of 81 of 5FY2025 · Scorecard6th of 80 of 5FY2025 · Scorecard8th of 81 of 5FY2025 · Scorecard6th of 82 of 5FY2025 · Scorecard4th of 833% passed8 ranked
Growth checks (Higher is better)1 of 6FY2025 · Scorecard6th of 80 of 2FY2025 · Scorecard8th of 85 of 6FY2025 · Scorecard1st of 81 of 6FY2025 · Scorecard6th of 83 of 5FY2025 · Scorecard3rd of 81 of 2FY2025 · Scorecard5th of 83 of 5FY2025 · Scorecard3rd of 84 of 6FY2025 · Scorecard2nd of 855% passed8 ranked
Profitability checks (Higher is better)4 of 5FY2025 · Scorecard2nd of 80 of 3FY2025 · Scorecard6th of 85 of 6FY2025 · Scorecard1st of 83 of 6FY2025 · Scorecard3rd of 82 of 5FY2025 · Scorecard4th of 80 of 2FY2025 · Scorecard6th of 81 of 5FY2025 · Scorecard5th of 80 of 5FY2025 · Scorecard6th of 830% passed8 ranked
Financial health checks (Higher is better)2 of 4FY2025 · Scorecard3rd of 81 of 2FY2025 · Scorecard3rd of 85 of 5FY2025 · Scorecard1st of 82 of 5FY2025 · Scorecard7th of 82 of 4FY2025 · Scorecard3rd of 82 of 2FY2025 · Scorecard1st of 82 of 6FY2025 · Scorecard8th of 82 of 4FY2025 · Scorecard3rd of 850% passed8 ranked
Shareholder returns checks (Higher is better)5 of 5FY2025 · Scorecard1st of 71 of 1FY2025 · Scorecard1st of 72 of 3FY2025 · Scorecard3rd of 72 of 3FY2025 · Scorecard3rd of 70 of 1FY2025 · Scorecard5th of 7——0 of 1FY2025 · Scorecard5th of 70 of 1FY2025 · Scorecard5th of 767% passed7 ranked
Ownership
Held by institutions (Better neither way: ranked highest first)92.2%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in2nd of 833.8%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in7th of 871.8%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in5th of 889.1%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in4th of 850.9%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in6th of 811.6%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in8th of 890.3%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in3rd of 896.7%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in1st of 880.5%8 ranked
Institutions holding (Better neither way: ranked highest first)3212026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in1st of 8872026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in7th of 81682026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in4th of 81872026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in3rd of 81192026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in6th of 8502026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in8th of 82202026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in2nd of 81362026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in5th of 81528 ranked
Institutional holding, change over the quarter (Better neither way: ranked highest first)-13.3 pp2026-Q2 against 2026-Q1 · 13F8th of 8-3.4 pp2026-Q2 against 2026-Q1 · 13F7th of 8+6.5 pp2026-Q2 against 2026-Q1 · 13F2nd of 8+3.7 pp2026-Q2 against 2026-Q1 · 13F4th of 8-0.5 pp2026-Q2 against 2026-Q1 · 13F6th of 8+2.2 pp2026-Q2 against 2026-Q1 · 13F5th of 8+25.4 pp2026-Q2 against 2026-Q1 · 13F1st of 8+4.9 pp2026-Q2 against 2026-Q1 · 13F3rd of 8+2.9 pp8 ranked
Dividends
Dividend yield (Higher is better)9.6%FY2025 · SEConly one with it95th93rd————————————————————————————9.6%—
Shareholder yield (Higher is better)9.6%FY2025 · SEC1st of 388th87th————3.6%FY2025 · SEC3rd of 364th55th6.8%FY2025 · SEC2nd of 382nd78th————————————————6.8%3 ranked
Dividend payout (Better neither way: ranked highest first)36.7%FY2025 · SEConly one with it67th49th————————————————————————————36.7%—
Dividend per share (Better neither way: ranked highest first)$0.60FY2025 · SEConly one with it——————————————$0.60—

Under each figure: its fiscal year, quarter or date, and its source. ↑ higher is better, ↓ lower is better, · better neither way (ranked highest first). Ranks count only the companies with the figure; percentiles place each company among all the companies of its own sector and country with the figure (ten or more needed).

Key: SEC = SEC annual reports (10-K, 20-F, 40-F); ESEF = ESEF annual reports (European and UK listed companies); Editors = The company's annual report, entered by value.today editors; Wikidata = Wikidata, citing the annual report; Scorecard = value.today scorecard: thirty checks on the company's statements, worked out daily; 13F = SEC Form 13F holdings reports; SEC = Dividends declared per share in SEC 10-Q and 10-K filings; Profile = The company's latest reported headcount; Market data = Embecta Corp.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Nautilus Biotechnology, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Viemed Healthcare, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Emergent BioSolutions Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Fennec Pharmaceuticals Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; CapsoVision, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Editas Medicine, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Orthofix Medical Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover.

Where each stands in its sector and country: Operating margin#

The dot is the company; the line runs from the 10th to the 90th percentile of all the companies of its sector (or country) with the figure, the box holds the middle half and the tick is the median. Each company's newest fiscal year; figures that divide by the market value only with a market cap at most 60 days old. How percentiles are worked out.

Operating margin: each company's figure and its percentile in its sector and its country
CompanyOperating marginIn its sectorIn its country
Embecta Corp.22.4%FY2025
91st percentile in Healthcaremedian -8.0%, 684 companies
88th percentile in USAmedian 3.4%, 2,607 companies
Nautilus Biotechnology, Inc.———
Viemed Healthcare, Inc.8.5%FY2025
71st percentile in Healthcaremedian -8.0%, 684 companies
64th percentile in USAmedian 3.4%, 2,607 companies
Emergent BioSolutions Inc.13.5%FY2025
80th percentile in Healthcaremedian -8.0%, 684 companies
75th percentile in USAmedian 3.4%, 2,607 companies
Fennec Pharmaceuticals Inc.-14.1%FY2025
45th percentile in Healthcaremedian -8.0%, 684 companies
24th percentile in USAmedian 3.4%, 2,607 companies
CapsoVision, Inc.-188.3%FY2025
16th percentile in Healthcaremedian -8.0%, 684 companies
6th percentile in USAmedian 3.4%, 2,607 companies
Editas Medicine, Inc.-394.9%FY2025
8th percentile in Healthcaremedian -8.0%, 684 companies
3rd percentile in USAmedian 3.4%, 2,607 companies
Orthofix Medical Inc.-9.9%FY2025
49th percentile in Healthcaremedian -8.0%, 684 companies
28th percentile in USAmedian 3.4%, 2,607 companies

Revenue by fiscal year, and the rank in the group#

Revenue of the fiscal year. US dollars at each year's exchange rate; fiscal years as each company names them. Ranks: 1st is the highest (better neither way).

Revenue

$0 M$443 M$887 M$1.3 B$1.8 B20102012201420162018202020222024Embecta Corp. $1.1 BViemed Healthcare, Inc. $270 MEmergent BioSolutions Inc. $743 MFennec Pharmaceuticals Inc. $45 MCapsoVision, Inc. $14 MEditas Medicine, Inc. $41 MOrthofix Medical Inc. $822 M

Rank in the group

1st2nd3rd4th5th6th7th201120122013201420152016201720182019202020212022202320242025Embecta Corp.: 2nd of 5 in 2020Embecta Corp.: 2nd of 5 in 2021Embecta Corp.: 1st of 6 in 2022Embecta Corp.: 1st of 6 in 2023Embecta Corp.: 1st of 7 in 2024Embecta Corp.: 1st of 7 in 2025Embecta Corp.Viemed Healthcare, Inc.: 3rd of 4 in 2018Viemed Healthcare, Inc.: 3rd of 4 in 2019Viemed Healthcare, Inc.: 4th of 5 in 2020Viemed Healthcare, Inc.: 4th of 5 in 2021Viemed Healthcare, Inc.: 4th of 6 in 2022Viemed Healthcare, Inc.: 4th of 6 in 2023Viemed Healthcare, Inc.: 4th of 7 in 2024Viemed Healthcare, Inc.: 4th of 7 in 2025Viemed Healthcare, Inc.Emergent BioSolutions Inc.: 2nd of 2 in 2011Emergent BioSolutions Inc.: 2nd of 2 in 2012Emergent BioSolutions Inc.: 2nd of 2 in 2013Emergent BioSolutions Inc.: 1st of 2 in 2014Emergent BioSolutions Inc.: 1st of 2 in 2015Emergent BioSolutions Inc.: 1st of 3 in 2016Emergent BioSolutions Inc.: 1st of 3 in 2017Emergent BioSolutions Inc.: 1st of 4 in 2018Emergent BioSolutions Inc.: 1st of 4 in 2019Emergent BioSolutions Inc.: 1st of 5 in 2020Emergent BioSolutions Inc.: 1st of 5 in 2021Emergent BioSolutions Inc.: 2nd of 6 in 2022Emergent BioSolutions Inc.: 2nd of 6 in 2023Emergent BioSolutions Inc.: 2nd of 7 in 2024Emergent BioSolutions Inc.: 3rd of 7 in 2025Emergent BioSolutions Inc.Fennec Pharmaceuticals Inc.: 5th of 5 in 2020Fennec Pharmaceuticals Inc.: 6th of 6 in 2022Fennec Pharmaceuticals Inc.: 6th of 6 in 2023Fennec Pharmaceuticals Inc.: 5th of 7 in 2024Fennec Pharmaceuticals Inc.: 5th of 7 in 2025Fennec Pharmaceuticals IncCapsoVision, Inc.: 7th of 7 in 2024CapsoVision, Inc.: 7th of 7 in 2025CapsoVision, Inc.Editas Medicine, Inc.: 3rd of 3 in 2016Editas Medicine, Inc.: 3rd of 3 in 2017Editas Medicine, Inc.: 4th of 4 in 2018Editas Medicine, Inc.: 4th of 4 in 2019Editas Medicine, Inc.: 5th of 5 in 2021Editas Medicine, Inc.: 5th of 6 in 2022Editas Medicine, Inc.: 5th of 6 in 2023Editas Medicine, Inc.: 6th of 7 in 2024Editas Medicine, Inc.: 6th of 7 in 2025Editas Medicine, Inc.Orthofix Medical Inc.: 1st of 2 in 2011Orthofix Medical Inc.: 1st of 2 in 2012Orthofix Medical Inc.: 1st of 2 in 2013Orthofix Medical Inc.: 2nd of 2 in 2014Orthofix Medical Inc.: 2nd of 2 in 2015Orthofix Medical Inc.: 2nd of 3 in 2016Orthofix Medical Inc.: 2nd of 3 in 2017Orthofix Medical Inc.: 2nd of 4 in 2018Orthofix Medical Inc.: 2nd of 4 in 2019Orthofix Medical Inc.: 3rd of 5 in 2020Orthofix Medical Inc.: 3rd of 5 in 2021Orthofix Medical Inc.: 3rd of 6 in 2022Orthofix Medical Inc.: 3rd of 6 in 2023Orthofix Medical Inc.: 3rd of 7 in 2024Orthofix Medical Inc.: 2nd of 7 in 2025Orthofix Medical Inc.
Revenue by fiscal year with each company's rank in the group and the source of each figure
Fiscal yearEmbecta Corp.Nautilus Biotechnology, Inc.Viemed Healthcare, Inc.Emergent BioSolutions Inc.Fennec Pharmaceuticals Inc.CapsoVision, Inc.Editas Medicine, Inc.Orthofix Medical Inc.
2025$1.1 BSEC1st—$270 MSEC4th$743 MSEC3rd$45 MSEC5th$14 MSEC7th$41 MSEC6th$822 MSEC2nd
2024$1.1 BSEC1st—$224 MSEC4th$1.0 BSEC2nd$48 MSEC5th$12 MSEC7th$32 MSEC6th$799 MSEC3rd
2023$1.1 BSEC1st—$183 MSEC4th$1.0 BSEC2nd$21 MSEC6th—$78 MSEC5th$747 MSEC3rd
2022$1.1 BSEC1st—$139 MSEC4th$1.1 BSEC2nd$2 MSEC6th—$20 MSEC5th$461 MSEC3rd
2021$1.2 BSEC2nd—$117 MSEC4th$1.8 BSEC1st——$26 MSEC5th$464 MSEC3rd
2020$1.1 BSEC2nd—$131 MSEC4th$1.6 BSEC1st$0 MSEC5th——$407 MSEC3rd
2019——$80 MSEC3rd$1.1 BSEC1st——$21 MSEC4th$460 MSEC2nd
2018——$64 MSEC3rd$782 MSEC1st——$32 MSEC4th$453 MSEC2nd
2017———$561 MSEC1st——$14 MSEC3rd$434 MSEC2nd
2016———$489 MSEC1st——$6 MSEC3rd$410 MSEC2nd
2015———$523 MSEC1st———$396 MSEC2nd
2014———$450 MSEC1st———$402 MSEC2nd

Key: SEC = SEC annual reports (10-K, 20-F, 40-F); ESEF = ESEF annual reports (European and UK listed companies); Ed. = The company's annual report, entered by value.today editors; WD = Wikidata, citing the annual report; Cap = value.today market caps (the last of each calendar year). The small ordinal is the rank in the group that year. Hover a figure for its fiscal year end.

Suggested peers of Embecta Corp.#

Companies of the same industry first, then the same sector, within a hundred times its size (market cap), scored out of 100 for industry, size, country and figures on file. How peers are suggested.

  • Nautilus Biotechnology, Inc.NAUT · 🇺🇸 USA
    Same sector: Healthcare (Biotechnology) · Similar size: $368 M market cap against $366 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $368 M (Oct 28, 2026)
    75 of 100 (industry or sector 25 + size 30 + country 15 + figures on file 5)
    In the group
  • Viemed Healthcare, Inc.VMD · 🇺🇸 USA
    Same sector: Healthcare (Medical Equipment) · Similar size: $367 M market cap against $366 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $367 M (Oct 15, 2026) · revenue $270 M (year to December 2025)
    75 of 100 (industry or sector 25 + size 30 + country 15 + figures on file 5)
    In the group
  • Emergent BioSolutions Inc.EBS · 🇺🇸 USA
    Same sector: Healthcare (Pharmaceutical) · Similar size: $365 M market cap against $366 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $365 M (Oct 29, 2026) · revenue $743 M (year to December 2025)
    75 of 100 (industry or sector 25 + size 30 + country 15 + figures on file 5)
    In the group
  • Fennec Pharmaceuticals Inc.FENC · 🇺🇸 USA
    Same sector: Healthcare (Biotechnology) · Similar size: $374 M market cap against $366 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $374 M (Oct 31, 2026) · revenue $45 M (year to December 2025)
    75 of 100 (industry or sector 25 + size 30 + country 15 + figures on file 5)
    In the group
  • CapsoVision, Inc.CV · 🇺🇸 USA
    Same sector: Healthcare (Medical Devices) · Similar size: $372 M market cap against $366 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $372 M (Oct 30, 2026) · revenue $14 M (year to December 2025)
    75 of 100 (industry or sector 25 + size 30 + country 15 + figures on file 5)
    In the group
  • Editas Medicine, Inc.EDIT · 🇺🇸 USA
    Same sector: Healthcare (Biotechnology) · Similar size: $363 M market cap against $366 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $363 M (Oct 19, 2026) · revenue $41 M (year to December 2025)
    75 of 100 (industry or sector 25 + size 30 + country 15 + figures on file 5)
    In the group
  • Orthofix Medical Inc.OFIX · 🇺🇸 USA
    Same sector: Healthcare (Medical Devices) · Similar size: $377 M market cap against $366 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $377 M (Oct 15, 2026) · revenue $822 M (year to December 2025)
    75 of 100 (industry or sector 25 + size 30 + country 15 + figures on file 5)
    In the group
  • Community Health Systems, Inc.CYH · 🇺🇸 USA
    Same sector: Healthcare (Medical Care Facilities) · Similar size: $375 M market cap against $366 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $375 M (Oct 29, 2026) · revenue $12.5 B (year to December 2025)
    75 of 100 (industry or sector 25 + size 30 + country 15 + figures on file 5)
    + Add
  • ARS Pharmaceuticals, Inc.SPRY · 🇺🇸 USA
    Same sector: Healthcare (Biotechnology) · Similar size: $375 M market cap against $366 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $375 M (Oct 28, 2026) · revenue $84 M (year to December 2025)
    75 of 100 (industry or sector 25 + size 30 + country 15 + figures on file 5)
    + Add
  • Galectin Therapeutics Inc.GALT · 🇺🇸 USA
    Same sector: Healthcare (Biotechnology) · Similar size: $357 M market cap against $366 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $357 M (Oct 29, 2026)
    75 of 100 (industry or sector 25 + size 30 + country 15 + figures on file 5)
    + Add
  • Capricor Therapeutics, Inc.CAPR · 🇺🇸 USA
    Same sector: Healthcare (Biotechnology) · Similar size: $356 M market cap against $366 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $356 M (Oct 23, 2026) · revenue $0 M (year to December 2025)
    75 of 100 (industry or sector 25 + size 30 + country 15 + figures on file 5)
    + Add
  • Evolent Health, Inc.EVH · 🇺🇸 USA
    Same sector: Healthcare (Healthcare Information Services) · Similar size: $383 M market cap against $366 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $383 M (Oct 2, 2026) · revenue $1.9 B (year to December 2025)
    75 of 100 (industry or sector 25 + size 30 + country 15 + figures on file 5)
    + Add

Any figure over the years, other peers or a saved group: open this group in the peer workspace.